und ahnungslos, wie dein kollegev lucky...euch kann man mit 100 stücken, die 40% ausmachen ins boxhorn jagen.
junge, was wollt ihr an der börse?
junge, was wollt ihr an der börse?
Anzeige
Meldung des Tages: Nach Börsenschluss veröffentlicht – warum diese News erst Montag eingepreist werden kann
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht Alle
Zurück
Weiter
1 2 3 4 5 6
Antworten | Hot-Stocks-Forum Übersicht Alle
Zurück
Weiter 1 2 3 4 5 6
Calypte 2005 das Megajahr ?
Beiträge:
142
Zugriffe: 17.100 / Heute: 7
Zugriffe: 17.100 / Heute: 7
|
| ||||||||||||||
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +58,66%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +58,58%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +58,49%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +51,94%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +42,06%
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
hype mit ein paar stücken vorgespielt?
und, schon nachgekauft?
muahahahha
ihr hättet eure kröten besser mal bei den paar ausressertrades gesichert...
nein , aber natürlich nicht....muhahahahahhahaha
und schon geht es wieder runter:
Time & Sales most recent next page
Rec. Time Action Price Volume
9:42:58 AM Ask 0.37 200
9:42:56 AM Trade 0.37 7600
9:42:50 AM Trade 0.37 2400
9:42:50 AM Ask 0.38 29500
9:42:38 AM Bid 0.36 5000
9:42:34 AM Ask 0.37 2400
9:42:32 AM Ask 0.38 9000
9:42:30 AM Trade 0.37 20000
und, schon nachgekauft?
muahahahha
ihr hättet eure kröten besser mal bei den paar ausressertrades gesichert...
nein , aber natürlich nicht....muhahahahahhahaha
und schon geht es wieder runter:
Time & Sales most recent next page
Rec. Time Action Price Volume
9:42:58 AM Ask 0.37 200
9:42:56 AM Trade 0.37 7600
9:42:50 AM Trade 0.37 2400
9:42:50 AM Ask 0.38 29500
9:42:38 AM Bid 0.36 5000
9:42:34 AM Ask 0.37 2400
9:42:32 AM Ask 0.38 9000
9:42:30 AM Trade 0.37 20000
hä??????? was meinst du lucky? stammel nicht, sprich mal richtig, versuche es wenigstens mal!
einmalige ausstiegschance um die 0,40$ nochmal....aber dann solltet ihr auch glattstellen...
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
Jetzt sichern...
Two studies call for more HIV tests
Rapid testing firms may see benefit
By Kristen Gerencher, MarketWatch
Last Update: 7:25 PM ET Feb. 9, 2005
SAN FRANCISCO (MarketWatch) -- Shares of companies that make or distribute rapid HIV tests may get a boost from two studies that found expanding routine viral screening would be a cost-effective way to reduce transmission and improve public health.
Testing in areas where there's low prevalence of the virus that causes AIDS is affordable and prolongs the life of people carrying HIV without knowing it, according to a pair of studies to be published in the Feb. 10 edition of the New England Journal of Medicine.
Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure.
The studies -- one from Duke University and the Veterans Affairs Palo Alto Health Care System, and the other from researchers at Harvard and Yale -- were conducted independently of each other but show similar results. Both sets of researchers are calling for doctors and policymakers to expand HIV counseling, testing and referrals, especially now that a diagnosis more often yields a chronic disease managed with cocktails of antiretroviral drugs rather than a death sentence.
"While the Centers for Disease Control and Prevention's guidelines are that routine screenings are effective in settings where there is a 1 percent or above prevalence of disease, our analysis showed that such screening at much lower prevalence levels would provide important benefits," said Dr. Gillian Sanders, lead author of the Duke and Palo Alto VA report, in a statement. "In addition, we found this screening would be cost-effective and in line with other commonly accepted screening programs."
A. David Paltiel, associate professor of health policy and administration at Yale and lead author of the second study, agreed.
"The publication of these papers represents a golden opportunity to jump-start the expansion of HIV testing services in the United States," he said in a statement.
Two studies call for more HIV tests
Rapid testing firms may see benefit
By Kristen Gerencher, MarketWatch
Last Update: 7:25 PM ET Feb. 9, 2005
SAN FRANCISCO (MarketWatch) -- Shares of companies that make or distribute rapid HIV tests may get a boost from two studies that found expanding routine viral screening would be a cost-effective way to reduce transmission and improve public health.
Testing in areas where there's low prevalence of the virus that causes AIDS is affordable and prolongs the life of people carrying HIV without knowing it, according to a pair of studies to be published in the Feb. 10 edition of the New England Journal of Medicine.
Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure.
The studies -- one from Duke University and the Veterans Affairs Palo Alto Health Care System, and the other from researchers at Harvard and Yale -- were conducted independently of each other but show similar results. Both sets of researchers are calling for doctors and policymakers to expand HIV counseling, testing and referrals, especially now that a diagnosis more often yields a chronic disease managed with cocktails of antiretroviral drugs rather than a death sentence.
"While the Centers for Disease Control and Prevention's guidelines are that routine screenings are effective in settings where there is a 1 percent or above prevalence of disease, our analysis showed that such screening at much lower prevalence levels would provide important benefits," said Dr. Gillian Sanders, lead author of the Duke and Palo Alto VA report, in a statement. "In addition, we found this screening would be cost-effective and in line with other commonly accepted screening programs."
A. David Paltiel, associate professor of health policy and administration at Yale and lead author of the second study, agreed.
"The publication of these papers represents a golden opportunity to jump-start the expansion of HIV testing services in the United States," he said in a statement.
Jetzt sichern...
Two studies call for more HIV tests
Rapid testing firms may see benefit
By Kristen Gerencher, MarketWatch
Last Update: 7:25 PM ET Feb. 9, 2005
SAN FRANCISCO (MarketWatch) -- Shares of companies that make or distribute rapid HIV tests may get a boost from two studies that found expanding routine viral screening would be a cost-effective way to reduce transmission and improve public health.
Testing in areas where there's low prevalence of the virus that causes AIDS is affordable and prolongs the life of people carrying HIV without knowing it, according to a pair of studies to be published in the Feb. 10 edition of the New England Journal of Medicine.
Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure.
The studies -- one from Duke University and the Veterans Affairs Palo Alto Health Care System, and the other from researchers at Harvard and Yale -- were conducted independently of each other but show similar results. Both sets of researchers are calling for doctors and policymakers to expand HIV counseling, testing and referrals, especially now that a diagnosis more often yields a chronic disease managed with cocktails of antiretroviral drugs rather than a death sentence.
"While the Centers for Disease Control and Prevention's guidelines are that routine screenings are effective in settings where there is a 1 percent or above prevalence of disease, our analysis showed that such screening at much lower prevalence levels would provide important benefits," said Dr. Gillian Sanders, lead author of the Duke and Palo Alto VA report, in a statement. "In addition, we found this screening would be cost-effective and in line with other commonly accepted screening programs."
A. David Paltiel, associate professor of health policy and administration at Yale and lead author of the second study, agreed.
"The publication of these papers represents a golden opportunity to jump-start the expansion of HIV testing services in the United States," he said in a statement.
Two studies call for more HIV tests
Rapid testing firms may see benefit
By Kristen Gerencher, MarketWatch
Last Update: 7:25 PM ET Feb. 9, 2005
SAN FRANCISCO (MarketWatch) -- Shares of companies that make or distribute rapid HIV tests may get a boost from two studies that found expanding routine viral screening would be a cost-effective way to reduce transmission and improve public health.
Testing in areas where there's low prevalence of the virus that causes AIDS is affordable and prolongs the life of people carrying HIV without knowing it, according to a pair of studies to be published in the Feb. 10 edition of the New England Journal of Medicine.
Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure.
The studies -- one from Duke University and the Veterans Affairs Palo Alto Health Care System, and the other from researchers at Harvard and Yale -- were conducted independently of each other but show similar results. Both sets of researchers are calling for doctors and policymakers to expand HIV counseling, testing and referrals, especially now that a diagnosis more often yields a chronic disease managed with cocktails of antiretroviral drugs rather than a death sentence.
"While the Centers for Disease Control and Prevention's guidelines are that routine screenings are effective in settings where there is a 1 percent or above prevalence of disease, our analysis showed that such screening at much lower prevalence levels would provide important benefits," said Dr. Gillian Sanders, lead author of the Duke and Palo Alto VA report, in a statement. "In addition, we found this screening would be cost-effective and in line with other commonly accepted screening programs."
A. David Paltiel, associate professor of health policy and administration at Yale and lead author of the second study, agreed.
"The publication of these papers represents a golden opportunity to jump-start the expansion of HIV testing services in the United States," he said in a statement.
Gelöschter Beitrag.
Einblenden
»
#89
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
mit den ihr eben getönt habt? vielleicht erwähnt ihr mal, das das auch nur ein fehltrade mit 100 stück war. aber die ehrlichkeit bringt ihr nicht auf.
...Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure....
...Among the companies that may benefit are OraSure Technologies (OSUR: news, chart, profile) , which makes rapid HIV tests, and Abbott Laboratories (ABT: news, chart, profile) , which has a licensing agreement with OraSure....
Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy
aber das ist auch nicht ohne oder??
weise neue "investoren" für deinen schrott gewinnen?
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
weise neue "investoren" für deinen schrott gewinnen?
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
weise neue "investoren" für deinen schrott gewinnen?
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
du weißt genau, das die 0,49 oder 40% nur mit einem trade über lachhafte 100 stück zustande kamen. aber so lockt man zumindestens ahnungslose unwissende an, nicht...
aber gut, 11,43% sind auch schon was. ihr werdet alle eure chance bekommen, um die 0,40 zu verkaufen. den höchsten punkt erwischt man selten...
ist das ne beleidigung an caly oder ach nein er soll nen grünen bekommen... *gg*
euch nur abzockt, sie werden keine verkäufe bringen, was bringen dir die besten testergebnisse?
sie müssen endlich mal anfangen, das zeug zu verkaufen, aber so werdet ihr quartal für quartal, jahr für jahr hingehalten.
sie müssen endlich mal anfangen, das zeug zu verkaufen, aber so werdet ihr quartal für quartal, jahr für jahr hingehalten.
Time & Sales most recent next page
Rec. Time Action Price Volume
11:48:52 AM Bid 0.37 13500
11:48:28 AM Bid 0.37 8500
11:47:36 AM Trade 0.37 1500
11:47:14 AM Ask 0.38 46500
11:45:22 AM Trade 0.37 500
11:44:08 AM Trade 0.37 1500
11:42:10 AM Trade 0.38 400
11:42:10 AM Ask 0.38 48000
11:38:16 AM Ask 0.38 48400
11:36:30 AM Bid 0.37 6000
11:36:26 AM Bid 0.37 3000
Rec. Time Action Price Volume
11:48:52 AM Bid 0.37 13500
11:48:28 AM Bid 0.37 8500
11:47:36 AM Trade 0.37 1500
11:47:14 AM Ask 0.38 46500
11:45:22 AM Trade 0.37 500
11:44:08 AM Trade 0.37 1500
11:42:10 AM Trade 0.38 400
11:42:10 AM Ask 0.38 48000
11:38:16 AM Ask 0.38 48400
11:36:30 AM Bid 0.37 6000
11:36:26 AM Bid 0.37 3000
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Calypte Biomedical Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 97 | Wer wird der ARIVA-Trader 2003? | Happy End | ich_will | 25.04.21 10:38 | ||
3 | 153 | Der Calypte-Thread | buran | buran | 25.04.21 01:34 | |
| 6 | Calypte Biomedical, Deckel gebrochen 250% im Plus! | Börsenfan | buran | 10.06.13 23:36 | ||
| 1 | Abwarten, ist noch nicht aller Tage Abend | Volli | Volli | 25.10.11 15:49 | ||
| 2 | 49 | Calypte AIDS Studie erfolgreich 400 % WKN: 765254 | schubby1 | Volli | 30.06.11 16:36 |